

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

Vimentin (D21H3) XP Rabbit mAb (Alexa Fluor 555 Conjugate)

RRID:AB_10859896

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9855, RRID:AB_10859896

Antibody Information

URL: http://antibodyregistry.org/AB_10859896

Proper Citation: Cell Signaling Technology Cat# 9855, RRID:AB_10859896

Target Antigen: Vimentin (D21H3) XP Rabbit mAb (Alexa Fluor 555 Conjugate)

Host Organism: rabbit

Clonality: monoclonal

Comments: Applications: IF-IC

Antibody Name: Vimentin (D21H3) XP Rabbit mAb (Alexa Fluor 555 Conjugate)

Description: This monoclonal targets Vimentin (D21H3) XP Rabbit mAb (Alexa Fluor 555 Conjugate)

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_10859896

Vendor: Cell Signaling Technology

Catalog Number: 9855

Record Creation Time: 20250820T000852+0000

Record Last Update: 20250820T073020+0000

Ratings and Alerts

No rating or validation information has been found for Vimentin (D21H3) XP Rabbit mAb (Alexa Fluor 555 Conjugate).

No alerts have been found for Vimentin (D21H3) XP Rabbit mAb (Alexa Fluor 555 Conjugate).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Afenteva D, et al. (2025) Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer. Cell reports. Medicine, 6(9), 102316.

Launonen IM, et al. (2024) Chemotherapy induces myeloid-driven spatially confined T??cell exhaustion in ovarian cancer. Cancer cell, 42(12), 2045.

Lin JR, et al. (2023) Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer. Cell, 186(2), 363.

Wu HJ, et al. (2022) Spatial intra-tumor heterogeneity is associated with survival of lung adenocarcinoma patients. Cell genomics, 2(8).

Ringel AE, et al. (2020) Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. Cell, 183(7), 1848.

Hafner M, et al. (2019) Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity. Cell chemical biology, 26(8), 1067.

Lin JR, et al. (2018) Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes. eLife, 7.